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Mental retardation (MR) occurs in 2%–3% of the general population. Conventional karyotyping has a resolution
of 5–10 million bases and detects chromosomal alterations in ∼5% of individuals with unexplained MR. The
frequency of smaller submicroscopic chromosomal alterations in these patients is unknown. Novel molecular
karyotyping methods, such as array-based comparative genomic hybridization (array CGH), can detect submicro-
scopic chromosome alterations at a resolution of 100 kb. In this study, 100 patients with unexplained MR were
analyzed using array CGH for DNA copy-number changes by use of a novel tiling-resolution genomewidemicroarray
containing 32,447 bacterial artiﬁcial clones. Alterations were validated by ﬂuorescence in situ hybridization and/
or multiplex ligation-dependent probe ampliﬁcation, and parents were tested to determine de novo occurrence.
Reproducible DNA copy-number changes were present in 97% of patients. The majority of these alterations were
inherited from phenotypically normal parents, which reﬂects normal large-scale copy-number variation. In 10%
of the patients, de novo alterations considered to be clinically relevant were found: seven deletions and three
duplications. These alterations varied in size from 540 kb to 12 Mb and were scattered throughout the genome.
Our results indicate that the diagnostic yield of this approach in the general population of patients with MR is at
least twice as high as that of standard GTG-banded karyotyping.
Introduction
Mental retardation (MR) occurs in 2%–3%of newborns
in the general population, but, in most cases, its cause
has remained elusive (Roeleveld et al. 1997; Yeargin-
Allsopp et al. 1997). Establishing the cause in a mentally
retarded individual improves clinical management and
facilitates genetic counseling of the family. Chromosome
abnormalities are detectable by microscopic analysis of
chromosomes isolated from peripheral blood lympho-
cytes in ∼5% of patients with unexplained MR (Phelan
et al. 1996; de Vries et al. 1997; Schinzel 2001). The
resolution of microscopic techniques for detection of
abnormal karyotypes is typically in the range of 5–10
Mb. Molecular cytogenetic techniques, such as FISH
and multiplex ligation-dependent probe ampliﬁcation
(MLPA) (Schouten et al. 2002), have shown that caus-
ative submicroscopic rearrangements of the subtelomeric
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regions can be found in ∼5% of patients with human
malformations and MR (Flint et al. 1995; Knight et al.
1999; De Vries et al. 2003; Koolen et al. 2004a). These
results for the subtelomeric regions indicate that sub-
microscopic rearrangements in general may be a more
common cause of MR than microscopically visible
rearrangements.
Recent technological developments allow the inves-
tigation of the human genome at a resolution that is
∼50–100 times higher than that of routine chromosome
analysis by karyotyping (Pinkel et al. 1998; Lucito et
al. 2003; Ishkanian et al. 2004; Ried 2004). Such DNA-
based methods are collectively referred to as “molecular
karyotyping.” One such method is array-based com-
parative genomic hybridization (array CGH) (Solinas-
Toldo et al. 1997; Pinkel et al. 1998; Veltman et al.
2002). Pilot studies using intermediate resolution (1-
Mb) array CGH have indicated the potential of this
technology in diagnosing patients with MR and con-
genital anomalies (Vissers et al. 2003; Shaw-Smith et
al. 2004). Other recent studies have reported the pres-
ence of large-scale copy-number variations (LCVs) in
healthy individuals (Iafrate et al. 2004; Sebat et al.
2004), which could complicate the clinical interpreta-
tion of these genomic alterations.
The goal of the underlying study was to estimate the
signiﬁcance of this whole-genome approach for the gen-
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Table 1
Clinical Characteristics of the 100 Patients with MR
Characteristic Valuea
Sex:
Male 60
Female 40
Age group:
!10 years old 67
10–20 years old 23
120 years old 10
Age (years):
Median 7
Range 1–63
Level of MR:
Mild 32
Moderate 27
Severe 32
Not assessable 9
Family history of MR:
Yes:
Compatible with Mendelian inheritance 13
Incompatible with Mendelian inheritance 4
No 83
Prenatal-onset growth retardation:
Yes 18
No 82
Postnatal growth abnormalities:
Yes:
Head circumference or stature 42
Head circumference and stature 14
No 44
Facial dysmorphic features:
Yes:
1 Feature 19
2 Features 73
No 8
Nonfacial dysmorphism and congenital
abnormalities:
Yes:
1 Abnormality 35
2 Abnormalities 18
No 47
Total clinical score:
0 0
1 5
2 16
3 32
4 21
5 14
6 7
7 5
8–10 0
a Data are no. of patients, unless indicated otherwise.
Table 2
Clinical Checklist
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
eral population of patients with MR. Therefore, a re-
cently published, 32,447-clone BAC array, with com-
plete coverage of the entire human genome (Ishkanian
et al. 2004), was used for the ﬁrst time to test 100
mentally retarded patients, with or without additional
congenital malformations, for the presence of submi-
croscopic chromosomal alterations. Novel algorithms
were developed and validated for microarray normali-
zation and copy-number detection, and parental sam-
ples were used as a control population to distinguish
between causative de novo alterations and inherited
LCVs. A clinical evaluation of the patient sample used
in this study, in comparison with that of the overall
patient population seen in our clinical genetics center,
allowed us to estimate the importance of this approach
in medical practice.
Patients and Methods
Patients
The diagnostic value of the genomewide tiling-reso-
lution array CGH approach was tested by screening 100
patients with unexplainedMR (60males and 40 females;
age range 10 mo to 63 years) (table 1). All had normal
GTG-banded chromosomes, and all were previously
subjected to a speciﬁc subtelomeric screen using MLPA,
with normal results (Koolen et al. 2004a). All patients
were evaluated for additional clinical features by a
board-certiﬁed clinical geneticist. A clinical scoring sys-
tem based on the presence of family history of MR,
prenatal-onset growth retardation, postnatal growth re-
tardation or advanced growth, facial dysmorphic fea-
tures, and other congenital abnormalities was applied,
with a score from 0 to 10 (table 2) (Baralle 2001; de
Vries et al. 2001).
Genomic DNA was isolated from blood leukocytes
by use of routine procedures. For this study, two pools
of reference DNA were made—one containing equal
amounts of genomic DNA from 10 healthy male blood
donors and one containing equal amounts of genomic
DNA from 10 healthy female blood donors. Blood was
collected for DNA isolation from a total of 72 parents
for further analysis. This study was approved by the
Medical Ethics Committee of the Radboud University
Nijmegen Medical Centre.
Microarray Preparation
We prepared a tiling-resolution microarray consisting
of 32,447 overlapping BAC clones, which were selected
to cover the entire human genome (Ishkanian et al. 2004;
Krzywinski et al. 2004) and are available at the BACPAC
Resources Center Web site, using methodology essen-
tially as described elsewhere (Veltman et al. 2004). In
brief, genomic target DNAs were isolated from 1-ml bac-
terial cultures by use of an AutogenPrep 960 (Autogen),
in accordance with the instructions of the manufacturer.
Degenerate oligonucleotide-primed PCR (DOP-PCR)
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was performed on 50 ng of DNA from all clones, as
described elsewhere (Telenius et al. 1992), with minor
modiﬁcations (Veltman et al. 2002). DOP-PCR prod-
ucts were dissolved at a concentration of 1 mg/ml in a
30% dimethyl-sulfoxide solution and were spotted on-
to CMT-ultragaps coated glass slides (Corning) by use
of an Omnigrid 100 arrayer (Genomic Solutions). All
32,447 clones were printed once on a single microarray
slide.
Isolation of DNA and Microarray-Based Genome
Proﬁling
Isolation of genomic DNA, DNA labeling, hybridi-
zation of labeled DNA to the 32,447-BAC array, and
spot identiﬁcation were performed as described else-
where (Vissers et al. 2003). In brief, genomic DNA from
patients and controls was isolated in accordance with
standard procedures and was puriﬁed using a QIAamp
kit (QIAgen), in accordance with the instructions of the
manufacturer. Next, 500 ng of genomic DNA from each
patient was labeled by random priming with Cy3-dUTP
and Cy5-dUTP (Amersham Biosciences) and was hy-
bridized in duplicate with dye-swap against the sex-mis-
matched reference pool. Parental samples were hybrid-
ized once against the same reference pool as their child.
Test and reference samples were mixed with 120 mg of
human Cot-1 DNA (Roche), were coprecipitated, and
were resuspended in 120 ml of a hybridization solution
containing 50% formamide, 10% dextran sulfate, 2 #
saline sodium citrate (SSC), 4% SDS, and 10 mg/ml of
yeast tRNA (Invitrogen). Hybridization and posthybri-
dization washing procedures were performed using a
GeneTac Hybridization Station (Genomic Solutions). An
18-h hybridization at 37C with active circulation of the
probe was performed, followed by ﬁve posthybridization
wash cycles in 50% formamide and 2 # SSC at 45C
and ﬁve wash cycles in phosphate buffer at 20C. Slides
were dried by centrifugation and were scanned using a
GenePix Autoloader 4200AL laser scanner (Axon In-
struments). Spot identiﬁcation and two-color ﬂuores-
cence intensity measurements were obtained using the
GenePix 5.0 software, and all data were entered into a
database for subsequent analysis.
Data Analysis
The log2-transformed test :reference ratio for each
clone was normalized by subtracting its local mean log2
test:reference ratio obtained by a weighted median ﬁlter
(Yin and Yang 1996). This ﬁlter averages the log ratios
of autosomal clones weighted by a Gaussian distribution
with its mean at the spot to be normalized and an SD
of 1 physical mm on the array. The normalized ratios
were analyzed for loss and gain regions by a standard
hidden Markov model (HMM) (Rabiner 1989). This
HMM has three hidden states ( ) for each clone: normal,si
loss, and gain. The probability of ﬁnding the HMM in
a certain state, given normalized log ratios , is given byxi
p(sFx) ∝ p(xFs)p(s) p p(xFs )p(sFs ) , (1) i i i i1
i
where the transition probability is given by
Di⎧ ⎫⎪ ⎪(1 2e )/3 if s p si i1p(sFs ) p ,⎨ ⎬⎪ ⎪i i1 Di(1 e )/3 if s ( s⎩ ⎭i i1
where is the distance on the chromosome betweenD i
the adjacent clones i and . This equation has thei 1
following properties: (1) clones with identical chromo-
somal positions have identical states; (2) clones at an
inﬁnite distance from each other (e.g., located on dif-
ferent chromosomes) are noncorrelated; and (3) the tran-
sition probability for a distance 2 is the square of thatD i
for a distance . In this study, we used units of 150 MbD i
to measure the distances . The observed log ratio isD xi i
assumed to be Gaussian distributed, with SD and aj
mean that depends on its hidden state , as follows:si
p(xFnormal) p N(0,j)i
p(xFloss) p N(m,j)i
p(xFgain) p N(m,j) .i
The sex-mismatched hybridizations allowed us to use
the median of the log ratios of clones mapped to the
chromosome X as an internal estimate of a single-copy
gain or loss for each experiment and allowed a quick
objective general assessment of the quality of individual
experiments. For this reason, the sex chromosomes were
excluded from further analysis.
The SD of the log ratios of all autosomal clones was
used as an estimate for . For duplicate experiments, thej
means and SDs were computed per array, and the prob-
ability is the product of the two individual1 2p(x ,x Fs )i i i
Gaussian distributions. To ﬁnd the hidden state that best
matches the observations, we used a standard Viterbi
algorithm that optimizes equation (1) (Forney 1973).
This results in a path in which we ﬁnd regions of con-
secutive clones that are in the hidden gain or loss state.
To quantify the likelihood of a copy-number gain or loss
in a certain region, indexed by n, we compared the op-
timal log likelihood of the Viterbi path, , with the∗logp
log-likelihood in the absence of the region, . Thenlogp
“certainty” that a region contains a real copy-number
change was deﬁned as
∗ ncertainty p log (logp  logp ) .10
The experimental threshold for this certainty was set at
1.5 for the experiments done in duplicate. To exclude
individual false-positive results, we furthermore required
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that a region consist of at least three clone positions.
This HMM method was validated by randomly per-
muting all autosomal data and rerunning the algorithm
on the entire set. For single-slide experiments (parental
samples), this analysis resulted in the detection of eight
aberrations, whereas in the experiments in duplicate (pa-
tient samples), only two small aneusomic segments were
identiﬁed. By randomly permuting all data, we created
a database of microarray data for which no spatial cor-
rection is expected. Any aberration found can, therefore,
be interpreted as a false positive. By doing so, a valid
estimate of the expected number of false positives in each
experiment is obtained. In addition, an experiment in
duplicate was performed in which the male reference
pool was hybridized against the female reference pool.
Again, the HMM was run, and no signiﬁcant regions
with a copy-number gain or loss were found. From this,
we conclude that the reference pools themselves did not
contain pronounced gains or losses. From all these anal-
yses, we concluded that the criteria are highly conser-
vative and that, especially for the experiments in dupli-
cate, almost all regions that meet the criteria are excellent
candidates for being a true copy-number alteration.
Conﬁrmation Experiments
De novo chromosomal alterations were validated in
the individual patients by at least one other method:
MLPA (Schouten et al. 2002), with speciﬁcally designed
synthetic probe sets, and/or FISH. It was similarly con-
ﬁrmed that parental samples contained a normal copy
number for these chromosomal regions. For MLPA, we
developed one or four uniquely sized probes for each
region to be tested, in accordance with a protocol pro-
vided by MRC-Holland (all reagents for MLPA reac-
tion and subsequent PCR ampliﬁcation were purchased
from MRC-Holland). Ten probes were combined in one
MLPA assay, in combination with four standard control
probes. MLPA analysis was performed as described else-
where, with minor modiﬁcations (Koolen et al. 2004a).
In brief, 200–400 ng of DNA in a ﬁnal volume of 8 ml
was heated for 5 min at 98C. Equal amounts of probe
mix and SALSA hybridization buffer were added to each
sample, followed by heat denaturation for 1 min at 97C
and overnight incubation at 60C. Next, Ligation-65
mix was added and was incubated for 15 min at 54C.
After heat inactivation, the ligation products were am-
pliﬁed by PCRwith the use of the 6-FAM–labeled primer
set. Ampliﬁcation products were identiﬁed and quanti-
ﬁed by capillary electrophoresis on an ABI 3730 genetic
analyzer, using GeneMapper software (Applied Biosys-
tems). Data were normalized by dividing each probe’s
signal strength by the average signal strength of the sam-
ple. This normalized peak pattern was divided by the
average peak pattern of all samples in the same exper-
iment. Values for control wild-type peaks ( )n p 1,667
were centered at 1.0, with an SD of 0.06. The mean
5 SD was used as the threshold for copy-number changes
(1.3 for gains and 0.7 for losses).
In addition, each de novo DNA copy-number alter-
ation identiﬁed by array CGH was validated by FISH
analysis on ﬁxed metaphase spreads from the respective
patient and from his or her parents. In each region of
signiﬁcant DNA copy-number alteration, four clones—
also present on the array—were selected as probes in
the FISH validation assay. In brief, BAC DNAs were
ampliﬁed by DOP-PCR and were labeled with biotin by
use of random priming. Subsequent hybridizations were
performed overnight at 37C on an OmniSlide Thermal
Cycler System (Thermo Hybaid; Thermo Life Sciences),
in accordance with standard protocols. Detection of the
biotin-labeled probes was achieved using either strepta-
vidin-Cy3 (Amersham Biosciences) or avidin-FITC fol-
lowed by goat-a-avidin-FITC (Vector Laboratories). The
FISH slides were analyzed using a Leica DM RA ﬂuo-
rescence microscope.
Results
Identiﬁcation of Chromosomal Alterations
by Genomewide Tiling-Resolution Array CGH
Our sample set consisted of 100 patients with unex-
plained MR, all with normal chromosomes, as deter-
mined by routine karyotyping, and with normal subte-
lomeres, as determined by MLPA. DNA from each pa-
tient was labeled and hybridized in duplicate (with label
swap) against a sex-mismatched reference pool onto mi-
croarrays containing 32,447 human BAC clones, which
completely covered the entire human genome. For each
patient, ﬂuorescence ratios of the scanned images were
quantiﬁed and normalized. The two experiments for
each patient were merged, clones were ordered according
to their position on the human genome sequence, and
copy-number states (normal, gain, or loss) were assigned
to each clone by use of a validated HMM (see the “Pa-
tients and Methods” section). In ﬁgure 1, examples are
shown of genome proﬁles obtained using the tiling-res-
olution BAC arrays. A total of 274 DNA copy-number
alterations were identiﬁed in the 100 patients, with a
range from 0 to 9 alterations per patient (ﬁg. 2). Only
three patients in this series did not show any copy-num-
ber alterations. Aneusomic segments varied in size from
50 kb to 12 Mb and were covered by 3–118 adjacently
mapped clones present on the microarrays.
Distinguishing between Inherited and de Novo
Alterations
To distinguish clinically relevant copy-number alter-
ations from normal LCVs, 72 clinically normal parents
of the 100 patients were tested using the same tiling-
resolution microarrays. These parental samples served
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Figure 2 Frequency distribution of aneuploid segments per patient
Figure 1 Genomic proﬁles obtained by tiling-resolution array CGH for patients with MR. The arrays contained 32,447 human BAC
clones (indicated by small circles representing the log2-transformed and normalized test:reference intensity ratios [“2Log(T/R)”]), ordered from
1pter to Yqter in the two genome proﬁles and from pter to qter for individual chromosomes, on the basis of physical-mapping positions obtained
from the UCSC Genome Browser (May 2004 freeze). A, Examples of de novo alterations, including deletions and duplications, in patients 1,
4, 5, 6, 8, and 9. B, Inherited copy-number variations in patients 117 and 498, including the matching chromosome proﬁles of one of their
parents. The individual chromosome plots show small horizontal lines to indicate the presence of a copy-number alteration (gain shown in
green; loss shown in red) detected by HMM analysis. Single-clone changes were ignored.
as a control population and, in addition, provided val-
uable information on the inheritance of speciﬁc copy-
number changes. Eleven alterations, detected in 10 in-
dividual patients (including two adjacent alterations in
patient 9), were present in neither of the parental DNA
samples nor in DNA from any of the 70 other unrelated
parents tested (table 3). These de novo alterations most
likely represent clinically relevant alterations. For ﬁve
other alterations, de novo occurrence could not be es-
tablished, as one or both of the patients’ parents were
not available; however, these alterations were never ob-
served in any of the other parents tested (table 3). For
these alterations, it remains unclear whether they are
clinically relevant. All 258 remaining alterations de-
tected in this study were shown to occur in at least one
of the normal parents tested (table 4). Such inherited
alterations most likely represent LCVs that are not re-
lated to the disorder under investigation. De novo aneu-
somic segments ranged in genomic size from 0.54 to
12.37 Mb (median 2.76 Mb), whereas LCVs ranged in
size from 0.05 to 2.16 Mb (median 0.43 Mb) (P p
, by two-sided independent student T test) (ﬁg. 3)..015
This suggests that clinically relevant aberrations are, in
general, larger than normal genomic variants. The larg-
est polymorphic variant detected in this study consisted
of two adjacently located duplications on chromosome
5p14.3, involving a total of 3.55 Mb.
Conﬁrmation Studies and Molecular Description
of Clinically Relevant Aberrations
All de novo chromosomal alterations were validated
in the individual patients by at least one other method:
FISH and/or MLPA. Parental samples were similarly
checked to conﬁrm that they contained a normal copy-
number for these chromosomal regions (table 2 and ﬁgs.
A1–A10 in appendix A [online only]). In addition, the
presence of a copy-number alteration was conﬁrmed in
four patient-parents trios with inherited copy-number
variations, in addition to four alterations detected in
patients for whom no parents were available for testing.
In all cases, these MLPA and FISH studies conﬁrmed the
aberrations predicted by array CGH analysis.
DNA from 10 patients contained validated de novo
segmental aneusomies: seven deletions and three dupli-
cations. The aneusomic segments identiﬁed varied in ge-
nomic size from 540 kb to 12 Mb, and they were scat-
tered throughout the genome. In all but one patient, the
de novo alteration involved a single genomic segment of
adjacent DNA clones. DNA from patient 9 contained a
complex duplication on the short arm of chromosome
17, consisting of four interspersed regions covering a
total of 8.93 Mb (table 3 and ﬁgs. 1 and A9 [online
only]). For this patient, one of the regions involved en-
compasses a known microduplication of the PMP22
gene associated with Charcot-Marie-tooth disease (CMT
[MIM 118220]). Another known microdeletion region
was observed in patient 10 at 22q11, the region asso-
ciated with classical DiGeorge syndrome (MIM 188400)
and velocardiofacial syndrome (VCFS [MIM 192430]).
The other chromosomal alterations did not map to
known microdeletion/duplication regions. Two of these
alterations had a genomic size !1 Mb—one deletion of
920 kb on 2q23.1-q23.2 (in patient 2) and one deletion
of 540 kb on 9q33.1 (in patient 6).
Clinical Implications of Tiling-Resolution Copy-Number
Screening
Clinical details of the individual patients are presented
in appendix A (online only) and are summarized in table
3. The study group included 32 patients with mild MR,
27 with moderate MR, and 32 with severe MR. In nine
patients, the level of MR was not accurately assessable,
mainly because of young age. The distribution of the
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Table 3
Patients with de Novo Alterations (Both Parents Tested) or Candidate Alterations (One or Both Parents Unavailable for Testing)
Type of
Submicroscopic
Aberration and
Chromosome Band Patient
Gain
or
Loss
Start
(Mb)
End
(Mb)
Length
(Mb)
No. of
Clonesa Conﬁrmedb Clinical Findings (Score)c
De novo:
1p34.3-1p34.2 1 Loss 39.22 43.15 3.93 42 Yes Severe MR, FD, GR, MC, and delayed brain
myelinization (7)
2q23.1-2q23.2 2 Loss 149.17 150.09 .92 11 Yes Severe MR, FD, GR, MC, BP, and epilepsy (3)
3q27.1-3q29 3 Loss 184.43 196.8 12.37 124 Yes Severe MR, FD, GR, MC, hypogenitalism,
hypoplastic kidneys, and deafness (6)
5q35.1 4 Gain 170.52 171.76 1.24 16 Yes Mild MR, semilobular holoprosencephaly,
ﬁnger-like thumbs, and polydactyly (3)
9q31.1 5 Loss 99.74 102.58 2.85 30 Yes Moderate MR, FD, MC, and transposition of
the great vessels (4)
9q33.1 6 Loss 115.3 115.84 .54 6 Yes Mild MR, FD, macrocephaly, and autistic
spectrum (3)
11q14.1-11q14.2 7 Loss 78.12 85.61 7.49 64 Yes Mild MR and FD (5)
12q24.21-12q24.23 8 Gain 114.91 117.21 2.3 39 Yes Severe MR, FD, GR, MC, and BP (7)
17p13.2-17p13.1 9 Gain 4.27 7.16 2.89 28 Not done Moderate MR and FD (3)d
17p13.1 9 Gain 7.67 9.10 1.43 14 Yes Moderate MR and FD (3)d
17p12 9 Gain 12.65 15.54 2.88 30 Yes Moderate MR and FD (3)d
17p11.2 9 Gain 18.55 20.03 1.48 24 Yes Moderate MR and FD (3)d
22q11.21 10 Loss 17.1 19.75 2.66 35 Yes Mild MR, FD, and GR (3)
Candidate:
1q21.1 11 Gain 143.25 145.38 2.12 21 Yes Moderate MR, FD, and GR (5)
3p14.1 12 Loss 67.59 68.15 .56 5 Yes Moderate MR (1)
7q11.21 13 Loss 64.23 64.58 .35 18 Not done Mild MR, FD, and BP (3)
9p24.3 14 Gain .21 .45 .23 5 Yes Moderate, MR, and FD (2)
15q24.1-15q24.2 15 Loss 72.21 73.86 1.65 16 Yes Mild MR, FD, GR, and MC (6)
NOTE.—None of the genomic regions were present in the Database of Genomic Variants (see Web Resources).
a Number of BAC clones located in the copy-number alteration.
b Conﬁrmed by MLPA and/or FISH.
c For detailed clinical descriptions, see appendix A (online only). The clinical checklist score is given in parentheses. BP p behavioral
problems; FD p facial dysmorphism; GR p growth retardation; MC p microcephaly.
d The same patient.
Table 4
All Polymorphic Variants Found in the 100 Patients
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
level of MR did not differ signiﬁcantly between the
group of patients with a de novo copy-number altera-
tion ( ) and the patients with reliable cognitiven p 10
assessment ( ) ( by Mann-Whitney Un p 81 P p 1.00
test). In addition to MR, all patients were evaluated for
other clinical features by use of a clinical checklist (tables
1 and 2). The 10 patients with de novo alterations had
a mean score of 4.4  1.7, which was not signiﬁcantly
different from that of the remaining 90 patients without
detectable de novo aneusomic segments (mean score 3.6
 1.4) ( by Mann-Whitney U test). This impliesP p .17
that, on average, the patients with de novo alterations
did not have more clinical features suggestive of a chro-
mosomal disorder than did patients without such an
alteration. The distribution of the clinical scores of the
100 patients is shown in table 5.
The 100 patients tested by array CGH in the present
study were part of a series of 297 mentally retarded
patients previously tested for subtelomeric abnormalities
by use of MLPA. A subtelomeric aberration was found
in 14 (4.7%) of 297 patients (table 5). To ascertain the
representativeness of the current sample set for all pa-
tients with MR who were referred to our clinical genet-
ics center for cytogenetic analysis, we gathered informa-
tion on the 710 patients with unexplained MR (exclud-
ing Down syndrome) who were referred for karyotyping
during a 2-year period (September 2002 to September
2004). Within this group, 34 patients (4.8%) had a mi-
croscopically visible chromosomal abnormality. A total
of 120 unselected patients from the remaining 676 were
clinically scored (table 5). Their mean score of 2.2 
1.7 was signiﬁcantly less than that of the 100 patients
tested in the current study ( by Mann-Whit-P ! .0001
ney U test). Thus, the current detection rate of 10% in
our sample partly reﬂects clinical preselection based on
phenotypes with additional dysmorphic features and/or
growth abnormalities. The use of this genomewide til-
ing-resolution array CGH approach in an unselected
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Figure 3 Size distribution of chromosomal aberrations, divided
into de novo alterations ( ) and polymorphic variants (n p 10 n p
). Black horizontal bars indicate median size (de novo alteration258
median 2.76 Mb; genomic variant median 0.43 Mb).
sample of patients with MR will likely have a lower
yield of de novo microdeletions/duplications. To esti-
mate the expected yield of submicroscopic alterations
over the entire genome, including the subtelomeric re-
gions, within an unselected population of mentally re-
tarded patients, we calculated the frequencies of sub-
microscopic abnormalities for each clinical score among
the group of 100 individuals tested by array CGH and
the group of 297 tested by MLPA. These frequencies
were then used to estimate the expected frequency of
the submicroscopic aberrations for each clinical score
among 120 unselected patients with MR. On the basis
of bootstrapping with 1,500 replications, the overall es-
timated frequency of microdeletions/duplications in this
unselected series of mentally retarded patients who were
referred to our department for karyotyping is 7.3%
(95%CI 4.2%–10.3%). This is considerably higher than
the rate of microscopically visible deletions and dupli-
cations in this patient group (4.8%).
Discussion
In this study, we demonstrate that submicroscopic inter-
stitial chromosomal abnormalities are a frequent cause of
MR in patients with additional phenotypic features. In
a set of 100 patients who have unexplained MR with
or without congenital anomalies, 10 de novo aneusomic
segments were detected by use of a tiling-resolution ge-
nomewide BAC array. For an additional ﬁve alterations
detected, it is unknown whether the chromosome ab-
normality identiﬁed was de novo, because one or both
parents were unavailable for testing. The 10 validated
de novo copy-number alterations detected in this study
by genomewide tiling-resolution array CGH were not
detected by routine chromosome analysis or by quan-
titative analysis of the subtelomeric regions with the use
of MLPA. This can be explained by the fact that all de
novo alterations were interstitial and that 7 of the 10
abnormalities were !4 Mb (2 were !1 Mb). The tiling-
resolution array CGH approach used in this study has
a 10-fold increase in coverage over that of routinely used
1-Mb resolution BAC arrays with ∼3,000 clones (Vissers
et al. 2003; Shaw-Smith et al. 2004; Rosenberg et al.
2005). Therefore, it can be expected that the application
of this approach leads to an increase in diagnostic yield
for MR. Although, indeed, many more aberrations were
detected by this approach (on average, three per patient),
only two de novo aberrations !1Mb were detected. This
result might suggest that a reliable 1-Mb copy-number
screening could identify the majority of submicroscopic
anomalies related to MR. However, additional data are
needed before the percentage of deletions and duplica-
tions !1 Mb in patients with MR can be reliably as-
sessed. One added value of tiling-path resolution arrays,
moreover, lies in the robustness of the detection. A 1-
Mb duplication, for instance, will be detected by 10
clones present on the tiling-path resolution array, com-
pared with only 1 clone on a 1-Mb resolution array.
This results in a signiﬁcantly lower false-positive rate.
In fact, no false positives were detected in this study.
Furthermore, a tiling-path array approach results in a
more precise mapping of the start and endpoints of each
rearrangement, thus allowing detailed genotype-phe-
notype correlation assessments.
Conventional GTG-banded karyotyping detects chro-
mosomal alterations in ∼5% of individuals with un-
explainedMR. Recent studies involving techniques such
as telomeric FISH and MLPA have revealed that small
subtelomeric deletions and duplications occur in ∼5%
of clinically preselected individuals with unexplained
MR whose routine chromosome analysis was normal
(Biesecker 2002; de Vries et al. 2003; Koolen et al.
2004a). Combined, these studies suggest that chromo-
somal alterations, bothmicroscopic and submicroscopic
and interstitial as well as subtelomeric, are responsible
for 20% of cases of unexplainedMR.However, we need
to take into account that our series of 100 patients is
not representative of all patients with unexplained MR
who are referred to our clinical genetics department.
Correction for this clinical preselection suggests an over-
all incidence of ∼12% of chromosomal alterations in
this patient group, of which ∼7% are submicroscopic
(interstitial and subtelomeric combined). We conclude
that molecular karyotyping by tiling-resolution array
CGH will increase the diagnostic yield of chromosomal
abnormalities among mentally retarded individuals by
approximately twofold. This is probably a conservative
estimate, since aberrations on the X chromosome could
not be analyzed for the presence of genomic rearrange-
ments because of the sex-mismatched hybridizations
needed for quality control (see the “Patients and Meth-
ods” section). At present, the robustness of the tiling-
resolution array CGH procedure is such that these in-
ternal quality assessments are no longer required, thus
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Table 5
Estimated Frequencies of Submicroscopic Aberrations for Each Clinical Score, in the Study Cohorts and an Unselected Cohort
of Patients with MR
CLINICAL
SCORE
STUDY COHORTS
UNSELECTED COHORT
( )n p 120
Array CGH Tested
( )n p 100
MLPA Tested
( )n p 297
Combined
Prevalence
No. of
Patients
Estimated
Frequency of
Aberrations
No. of
Patients
No. of
Aberrations Prevalence
No. of
Patients
No. of
Aberrations Prevalence
0 0 0 .00 1 0 .00 .00 20 .0
1 5 0 .00 36 1 .03 .03 25 .7
2 16 0 .00 58 1 .02 .02 33 .6
3 32 5 .16 86 5 .06 .21 17 3.5
4 21 1 .05 62 1 .02 .06 14 .9
5 14 1 .07 32 4 .13 .19 4 .8
6 7 1 .14 15 1 .07 .20 5 1.0
7 5 2 .40 6 0 .00 .40 1 .4
8 0 0 .00 1 1 1.00 1.00 1 1.0
9 0 0 .00 0 0 .00 .00 0 .0
10 0 0 .00 0 0 .00 .00 0 .0
Total 100 10 .10 297 14 .05 .14 120 8.8
NOTE.—The estimations are based on the combined prevalences of the submicroscopic anomalies in the study cohorts.
allowing sex-matched hybridizations in a routine di-
agnostic setting.
The clinical consequences of submicroscopic de novo
copy-number alteration are determined by the kind of
alteration (deletion or duplication) and by the number
and function of genes affected by the dosage altera-
tion. Three patients had a de novo duplication varying
in size from 1.2 to 8.9 Mb, leading to trisomy of 7–50
genes. These patients were mildly to severely mentally
retarded, and two had brain abnormalities, which var-
ied from microcephaly to semilobar holoprosencephaly.
The duplication on chromosome 17p11.2-p13.2 (pa-
tient 9) was complex, since four separate regions were
involved, including the CMT critical region (Suter and
Scherer 2003). At age 6 years, this moderately retarded
girl had not yet developed signs of CMT. The seven de
novo deletions varied in size from 540 kb to 12.4 Mb.
The gene content of the affected chromosomal areas
varied from monosomy of 1 gene in patient 6 to mono-
somy of 170 genes in patient 3. The microdeletions at
2q23.1-q23.2 (patient 2) and 22q11.21 (patient 10)
have been described previously. The latter deletion is
involved in the DiGeorge syndrome and VCFS, which
is a well-known, common, and clinically recognizable
syndrome (Lindsay 2001). The 4-year-old boy with this
deletion had mild MR, short stature, and some sugges-
tive facial features but lacked diagnostic VCFS features,
such as cardiac anomalies, cleft palate, long/thin ﬁngers,
hypocalcemia, or thymic hypoplasia. This shows that
array CGH also aids in diagnosing atypical clinical pre-
sentation of common microdeletion syndromes. The
920-kb microdeletion on 2q23.1-q23.2 (in patient 2)
partly overlaps a microdeletion previously reported by
our group and determined using a 1-Mb resolution BAC
array (Vissers et al. 2003; Koolen et al. 2004b). Both
patients had severe MR, postnatal growth retardation,
microcephaly, coarse facies, and epilepsy. The overlap
in clinical features between the two patients with these
microdeletions may point to a new syndrome. Three
genes are located in the overlapping deletion region—
MBD5, EPC2, and KIF5C. Mice lacking the gene for
KIF5C, a neuronal kinesin enriched in motor neurons,
show a smaller brain size and a loss of peripheral neu-
rons (Kanai et al. 2000). MBD5 is a member of the
methyl CpG-binding-domain protein family speciﬁcally
expressed in the brain (Nagase et al. 2000; Roloff et al.
2003).
In addition to clinically relevant DNA copy-number
alterations, we detected 258 LCVs in our series of 100
patients. All these variations were also observed in one
or more normal parental samples. This ﬁnding conﬁrms
and extends recent reports of the frequency of LCVs in
normal individuals (Iafrate et al. 2004; Sebat et al.
2004). Such variation represents a novel class of poly-
morphisms within the human genome whose exact fre-
quency in different ethnic groups remains to be estab-
lished. In general, normal genomic variants were smaller
than clinically relevant copy-number alterations. It is
essential to rule out such submicroscopic variation, by
studying parental samples, before drawing any conclu-
sions about whether an aneusomic segment is causative
for theMR. In addition, it is important to checkwhether
such an alteration has been described previously in nor-
mal individuals, since this will reduce the likelihood that
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it is causative. Moreover, clinical comparison with pre-
viously described patients who have overlapping alter-
ations will aid in the clinical interpretation. Systematic
collection of information on the phenotypic effects of
rare submicroscopic alterations is urgently needed, now
that molecular karyotyping is becoming part of clinical
patient evaluation (see ECARUCA–European Cytoge-
neticists Association Register of Unbalanced Chromo-
some Aberrations Web site).
In conclusion, this study demonstrates, for the ﬁrst
time, the use of a tiling-resolution BAC array in the
diagnosis of unexplained MR in patients. We were able
to distinguish de novo alterations from inherited DNA
copy-number alterations, and we conﬁrmed all ﬁnd-
ings identiﬁed by the array CGH method. After correc-
tion for clinical preselection, our data show that the
percentage of submicroscopic rearrangements among
individuals with unexplained MR exceeds that of mi-
croscopically visible alterations. Offering molecular
karyotyping by array CGH to patients who have un-
explained MR, with or without congenital anomalies,
will therefore signiﬁcantly improve diagnostic yield,
leading to accurate diagnosis and genetic counseling.
Note added in proof.—The data discussed in this pub-
lication have been deposited in NCBI’s Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and
are accessible through GEO Series accession number
GSE3191.
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